Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2021 > Vol 2, №5 (2021) > The role of plant extract drugs in treatment of LUTS due to benign prostate enlargement. Clinical cases review

The role of plant extract drugs in treatment of LUTS due to benign prostate enlargement. Clinical cases review

Adel S. Al-Shukri , Stanislav V. Kostyukov , Albina V. Maksimova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

In this article covered in detail the problem of lower urinary tract symptoms (LUTS), due to benign prostatic enlargement. The mechanisms of etiology and pathogenesis of prostate hyperplasia are analyzed. The review is done of modern methods of treatment, such as surgical methods and conservative. Special attention is paid to plant extract drugs in therapy of LUTS. Have done the analysis of several clinical trials, they prove effectiveness and low percentage of side effects. Some clinical cases are considered, demonstrating the way of outpatient examination of patients with LUTS and how to choose the tactic of treatment witch based on anamnesis, laboratory and instrumental examination. What confirms the necessity of individual treatment for every patient. 

Key words: low urinary tract symptoms, plant extract drug, prostatic obstruction, uroflowmetry.

About the Author

Adel S. Al-Shukri 1 , Stanislav V. Kostyukov 1 , Albina V. Maksimova 1

1 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

References

1. Jung HB, Kim HJ, Cho ST. A current perspective on geriatric lower urinary tract dysfunction. Korean J Urology 2015; 56 (4): 266. https://pubmed.ncbi.nlm.nih.gov/25874039/
2. Korneev I.A., Alekseeva T.A., Al'-Shukri S.Kh., Pushkar' D.Iu. Simptomy nizhnikh mochevykh putei u muzhchin Severo-Zapadnogo regiona Rossiiskoi Federatsii: analiz rezul'tatov populiatsionnogo issledovaniia. Urologicheskie vedomosti. 2016; 6 (1): 5–9. DOI: 10.17816/uroved615-9 (in Russian).
3. Aliaev Iu.G., Gadzhieva Z.K., Rapoport L.M., Kazilov Iu.B. Medikamentoznoe lechenie simptomov nizhnikh mochevykh putei u muzhchin. Rol' uroselektivnosti v vybore preparata. Andrologiia i genital'naia khirurgiia. 2014; 1: 6–14. DOI: org/10. 17650/2070-9781-2014-1-6-14 (in Rus-sian).
4. Park HJ, Won JE, Sorsaburu S et al. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health 2013; 31 (3): 193–207. DOI: 10.5534/wjmh.2013.31.3.193
5. Kupelian V et al. Prevalence of lower urinary tract symptoms and eff ect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med 2006; 166: 2381. https://www.ncbi. nlm.nih.gov/pubmed/ 17130393
6. Chapple CR et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol 2008; 54: 563. https://www.ncbi.nlm. nih.gov/pubmed/ 18423969
7. Kalinina S.N., Burlaka O.O., Aleksandrov M.S., Vydrin P.S. Diagnostika i lechenie simptomov nizhnikh mochevykh putei i erektil'noi disfunktsii u bol'nykh dobrokachestvennoi giperplaziei predstatel'noi zhelezy. Urologicheskie vedomosti. 2018; 8 (1): 26–33. https://journals.eco-vector.com/uroved/article/ view/8695 (in Russian).
8. Kudriavtsev Iu.V., Sivkov A.V. Morfologicheskie izmeneniia v tkani predstatel'noi zhelezy pri dobrokachestvennoi giperplazii. Eksperimental'naia i klinicheskaia urologiia. 2010; 1. https://ecuro.ru/ journal/nomer-1-2010 (in Russian).
9. Toscano IL, Maciel LC, Martins FG et al. Transurethral resection of the prostate: Prospective randomized study of catheter removal after 24 or 48 hours following surgery. Braz J Urol 2001; 27: 144–7.
10. Madersbacher S et al. Is transurethral resection of the prostate still justifi ed. BJU Int 1999; 83: 227–37. https://pubmed.ncbi. nlm.nih.gov/10233485/
11. American Urological Association guidelines, 2020.
12. Stephan Madersbacher, Claus Roehrborn, Matthias Oelke .The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. Age and Ageing 2015; 44 (5): 745–55. DOI: 10.1093/ageing/afv077
13. Rasner P.I., Pushkar' D.Iu. Lechenie simptomov nizhnikh mochevykh putei u patsientov s dobrokachestvennoi giperplaziei predstatel'noi zhelezy: sovremennye mezhdunarodnye standarty. RMZh. 2021; 2 (in Russian).
14. Oelke M, Becher K, Castro-Diaz D et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 2015; 44 (5): 745–55. DOI: 10.1093/ageing/afv077
15. Kasian G.R., Konovalov I.V. Sovremennye vozmozhnosti kombinirovannoi terapii simptomov nizhnikh vyvodiashchikh putei na fone dobrokachestvennoi giperplazii predstatel'noi zhelezy u muzhchin. Issledovaniia i praktika v meditsine. 2016; 3 (2): 37–44. DOI: 10.17709/2409-2231-2016-3-2-5 (in Russian).
16. Zitoun OA, Farhat AMn, Mohamed MA et al. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors. Eur J Pharmacology 2020; 883: 173301. DOI: 10.1016/j.ejphar.2020. 173301
17. Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol 2015; 1: 7–17. https://pubmed.ncbi.nlm.nih.gov/26497339/
18. Martazinova S.K., Shcheplev P.A. Effektivnost' i bezopasnost' kombinirovannogo primeneniia al'fa1-adrenblokatora doksazozina i ingibitora fosfodiesterazy 5-go tipa udenafila u bol'nykh s dobrokachestvennoi giperplaziei predstatel'noi zhelezy. Andrologiia i genital'naia khirurgiia. 2021; 2 (in Russian).
19. Zhang J, Li X, Yang B et al. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urology 2019; 37: 143–53. DOI: 10.1007/s00345-018-2370-z
20. Gravchenko L.A., Geller L.N. Istoriia farmatsii: uchebno-metodicheskoe posobie. Irkutsk: IGMU, 2014 (in Russian).
21. Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sciences 2015; 126: 42–56. DOI: 10.1016/j.lfs.2015.01.023
22. Krivoborodov G.G., Tur E.I. Primenenie fitoterapii u bol'nykh dobrokachestvennoi giperplaziei prostaty i khronicheskim prostatitom. Meditsinskii Sovet. 2014; 19: 62–3. DOI: 10.21518/2079-701X-2014-19-62-63 (in Russian).
23. Ullah R, Wazir J, Hossain Md A. A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia. Wiener Klinische Wochenschrift 2021; 133: 153–62. DOI: 10.1007/s00508-020-01692-z
24. European Association of Urology, 2021.
25. Chaika A.V., Borodin A.D., Chernous V.A., Verbovoi P.P. Primenenie kompleksnogo fitopreparata "Tadimaks" v lechenii dobrokachestvennoi giperplazii predstatel'noi zhelezy. Mediko-sotsial'nye problemy sem'i. 2012; 17: 1. http://www.mifua.com/archive/article/35729 (in Russian).
26. Nusratulloev I.N., Odilov A.Iu., Erov Kh.U., Kholaliev A.A. Primenenie lekarstvennogo preparata "Tadimaks' pri lechenii dobrokachestvennoi giperplazii predstatel'noi zhelezy. Vestnik Avitsenny. 2009; 4: 41–3 (in Russian).
27. Al'-Shukri A.S., Kostiukov S.V. Vozmozhnosti fitoterapii v lechenii patsientov s simptomami nizhnikh mochevykh putei vsledstvie dobrokachestvennogo uvelicheniia predstatel'noi zhelezy. Urologicheskie vedomosti. 2020; 10 (4): 317–23. DOI: 10.17816/uroved48969 (in Russian).

For citation:Al-Shukri A.S., Kostyukov S.V., Maksimova A.V. The role of plant extract drugs in treatment of LUTS due to benign prostate enlargement. Clinical cases review. Clinical review for general practice. 2021; 5: 39­–44. DOI: 10.47407/kr2021.2.5.00070


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru